

## CMS announces final Medicare national coverage determination for Aduhelm<sup>™</sup> (aducanumab)

- On April 7, 2022, the Centers for Medicare and Medicaid Services (CMS) <u>announced</u> the final <u>National Coverage Determination (NCD)</u> policy for Medicare coverage of <u>Aduhelm</u> (aducanumab).
- The NCD policy states that Aduhelm will be provided under Medicare coverage only for patients participating in CMS-approved clinical studies when used as part of a CMS approved clinical trial.
  - This policy goes into effect immediately and also applies to any future FDA-approved monoclonal antibodies directed against amyloid for use in treating Alzheimer's disease (AD).
- CMS acknowledges that Alzheimer's disease affects many Medicare beneficiaries. However,
  CMS noted Aduhelm has not demonstrated a clinically meaningful improvement in health
  outcomes (i.e., cognition and function) for patients with Alzheimer's disease. Additionally, CMS
  noted Aduhelm has been associated with safety concerns including amyloid-related imaging
  abnormalities (ARIA) that can lead to bleeding or edema in the brain. CMS believes the guidance
  provides a pathway to Medicare coverage while additional evidence is developed.
- Aduhelm was approved by the Food and Drug Administration in June 2021.
- At least three other anti-amyloid monoclonal antibodies (gantenerumab, donanemab, and lecanemab) are in late-stage clinical trials and could launch in 2023. OptumRx will continue to monitor emerging clinical data on Aduhelm as well as other pipeline drugs for Alzheimer's disease and then inform our clients of further recommendations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.